However, despite the reported evidence that HDAC inhibitors inhibit STAT3 activation through abolishing STAT3-phosphorylation at Tyr705 in pathological conditions such as cancer and kidney fibrosis, the exact mechanism remains elusive. Here, HDAC9 is linked to cancer.